News Releases

May 7, 2015

RepliCel Life Sciences Selected to Present at Cavendish Global Health Impact Forum
Unique forum brings together leading family offices and foundations seeking impactful investment and philanthropic opportunities within healthcare and life sciences VANCOUVER, BC –  May... Read full article

April 29, 2015

RepliCel Announces 2014 Fourth Quarter and Year-End Financial Results
VANCOUVER, BC – April 29, 2015 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP), a clinical stage regenerative medicine company focused on the... Read full article

April 15, 2015

RepliCel Life Sciences Receives Approval to Conduct Clinical Trial for Patients with Chronic Achilles Tendinosis
The University of British Columbia Clinical Research Ethics Board Clears Clinical Trial to Proceed with Site Initiation and Patient Recruitment VANCOUVER, BC – April... Read full article

April 7, 2015

RepliCel Life Sciences Receives TSX Venture Exchange Approval to Extend Warrant Expiry Dates
VANCOUVER, BC – April 7, 2015 – RepliCel Life Sciences Inc. (the “Company” or “RepliCel”) (OTCQB: REPCF) (TSX.V: RP), a clinical stage regenerative medicine... Read full article

April 2, 2015

RepliCel Life Sciences Applies to Extend Warrant Expiry Dates
VANCOUVER, BC – April 2, 2015 – RepliCel Life Sciences Inc. (the “Company” or “RepliCel”) (OTCQB: REPCF) (TSX.V: RP), a clinical stage regenerative medicine... Read full article

March 23, 2015

RepliCel Meets with Japanese Pharmaceutical and Medical Devices Agency (PMDA)
As part of its Japanese partnering strategy, RepliCel seeks advice of Japanese regulators around its fibroblast platform VANCOUVER, BC – March, 23 – RepliCel... Read full article

March 12, 2015

RepliCel Life Sciences in Japan for Key Industry Meetings
RepliCel activity while in Japan includes co-presenting hair regeneration technology with partner, Shiseido, at the Congress of the Japanese Society for Regenerative Medicine VANCOUVER,... Read full article

February 23, 2015

RepliCel Submits Clinical Trial Application for its Dermatological Clinical Trial
Autologous cell therapy, RCS-01, to be investigated as a potential treatment for aged, UV-damaged skin VANCOUVER, BC – February 23, 2015 – RepliCel Life... Read full article

January 20, 2015

RepliCel Life Sciences to Present at 11th Annual Phacilitate Cell & Gene Therapy Forum in Washington, DC
VANCOUVER, BC – January 20, 2015 – RepliCel Life Sciences Inc. (TSX.V: RP) (OTCQB: REPCF), a clinical stage regenerative medicine company focused on the... Read full article

January 7, 2015

RepliCel Life Sciences to Present at Biotech Showcase 2015
Meetings focused on investors, analysts, and potential partners for RCS-01 and RCT-01 cell therapies VANCOUVER, BC – January 7, 2015 – RepliCel Life Sciences... Read full article